文献速递主动脉疾病

荷兰国家腹主动脉瘤手术后二次主动脉再干预数量:基于荷兰外科动脉瘤审计

National Numbers of Secondary Aortic Reinterventions after Primary Abdominal Aortic Aneurysm Surgery from the Dutch Surgical Aneurysm Audit.
PubMed 文献 · Ann Vasc Surg · 2020-04-24

该观察性研究纳入2016–2017年荷兰外科动脉瘤审计(DSAA)中所有接受二次主动脉再干预(SAR)的患者,分析其数量、特征及结局。SAR占全国所有腹主动脉瘤(AAA)手术的9.3%,择期、急性症状和破裂患者术后死亡率分别为3.4%、11%和29%。多数SAR发生在初次EVAR后,其中内血管封堵移植物占比过高。

要点

  • SAR占荷兰AAA手术的9.3%,内漏是首要指征(60%)。
  • SAR术后死亡率择期3.4%、急性症状11%、破裂29%。
  • 初次EVAR后SAR中内血管封堵移植物占比过高。

核心结论

  • 荷兰约十分之一的AAA手术为SAR,多数SAR发生在初次EVAR后,内血管封堵移植物占比过高,SAR术后死亡率与初次AAA修复相当。

研究设计与样本

  • 观察性研究纳入2016–2017年荷兰外科动脉瘤审计(DSAA)中所有接受SAR的患者,共691例,占同期全国AAA手术的9.3%。
  • 将SAR数据与2013年1月后登记的初次AAA修复数据合并,其中26%(n=181)可合并分析。

主要发现

  • SAR指征以内漏最常见(60%),SAR中66%采用EVAR完成。
  • SAR术后死亡率在择期、急性症状和破裂患者中分别为3.4%、11%和29%。
  • 可合并分析的181例中,93%(n=136)初次AAA修复为EVAR。
  • 初次EVAR使用的移植物类型包括镍钛/聚酯(62%)、镍钛/聚四氟乙烯(8%)、内血管封堵(21%)和其他(9%)。
  • 与全国市场份额相比,内血管封堵移植物在SAR中占比过高(OR 5.04,95%CI 3.44–7.38),镍钛/聚酯(OR 0.52,95%CI 0.38–0.71)和镍钛/聚四氟乙烯(OR 0.50,95%CI 0.29–0.89)占比过低。

关键数值与推荐

  • SAR占所有AAA手术的9.3%(77%择期/11%急性症状/12%破裂)。
  • SAR术后死亡率:择期3.4%、急性症状11%、破裂29%。
  • 内血管封堵移植物在SAR中的OR为5.04(95%CI 3.44–7.38)。

临床怎么用

  • 血管外科医生应关注EVAR术后内漏导致的SAR风险,尤其是使用内血管封堵移植物时。
  • SAR术后死亡率与初次AAA修复相当,需根据 urgency 评估手术风险。

局限性

  • 仅26%的SAR患者可与其初次AAA修复数据合并分析,样本量有限。
  • SAR登记始于2016年,随访时间较短,可能低估远期再干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term secondary aortic reinterventions (SARs) can be a sign of (lack of) effectiveness of abdominal aortic aneurysm (AAA) surgery. This study provides insight into the national number of SARs after primary AAA repair by endovascular aneurysm repair (EVAR) or by open surgical repair in the Netherlands. METHODS: Observational study included all patients undergoing SAR between 2016 and 2017, registered in the compulsory Dutch Surgical Aneurysm Audit (DSAA). The DSAA started in 2013, SARs are registered from 2016. Characteristics of SAR and postoperative outcomes (mortality/complications) were analyzed, stratified by urgency of SAR. Data of SARs were merged with data of their preceded primary AAA repair, registered in the DSAA after January 2013. In these patients undergoing SAR, treatment characteristics of the preceded primary AAA repair were additionally described, with focus on differences between stent grafts. RESULTS: Between 2016 and 2017, 691 patients underwent SAR, this concerned 9.3% of all AAA procedures (infrarenal/juxtarenal/suprarenal) in the Netherlands (77% elective/11% acute symptomatic/12% ruptured). Endoleak (60%) was the most frequent indication for SAR. SARs were performed with EVAR in 66%. Postoperative mortalities after SAR were 3.4%, 11%, and 29% in elective, acute symptomatic, and ruptured patients, respectively. In 26% (n = 181) of the patients undergoing SAR their primary AAA repair was performed after January 2013 and data of primary and SAR procedures could be merged. In 93% (n = 136), primary AAA repair was EVAR. Endografts primarily used were nitinol/polyester (62%), nitinol/polytetrafluoroethylene (8%), endovascular sealing (21%), and others (9%), compared with their national market share of 76% (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.38-0.71), 15% (OR, 0.50; CI, 0.29-0.89), 4.9% (OR, 5.04; CI, 3.44-7.38), and 4.1% (OR, 2.81; CI, 1.66-4.74), respectively. CONCLUSIONS: In the Netherlands, about one-tenth of the annual AAA procedures concerns an SAR. A quarter of this cohort had an SAR within 1-5 years after their primary AAA repair. Most SARs followed after primary EVAR procedures, in which an overrepresentation of endovascular sealing grafts was seen. Postoperative mortality after SAR is comparable with primary AAA repair.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Karthaus EG, Vahl A, Elsman BHP, et al. National Numbers of Secondary Aortic Reinterventions after Primary Abdominal Aortic Aneurysm Surgery from the Dutch Surgical Aneurysm Audit. Ann Vasc Surg. 2020. PMID: 32335253. doi:10.1016/j.avsg.2020.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。